Healthcare

The Mystery Why Many Diets, Weight Loss Drugs Fail May Be Solved, New Study Suggests

Wikimedia Foundation

New epigenetic research reportedly suggests that the reason many diets and weight loss drugs fail is because fat cells retain memory of an obese state, even after weight loss occurs.

A recent experiment conducted on mice studied a chemical mechanism in fat cells — in which the hormone asprosin present in the tissue that induces hunger, triggers an expression in the DNA, and creates a “biological memory” within the cell, the Washington Post reported Monday.

Weight-loss drugs such as Ozempic, have risen in popular use in the United States for their dramatic effects, leading to a national decline in obesity rates according to recent polls. Eleven percent of U.S. adults take GLP-1 medications for weight loss purposes, up from three percent use in 2024, a Gallup poll released in July found.

However, many users report the effects wearing off quickly after slowing down or stopping the medication, according to research from JAMA Internal Medicine.

Eighty-three percent of users who lost weight using the weight loss drug tirzepatide reported regaining 25 percent or more of their initial weight loss within a year of stopping use of the the drug, a study published in JAMA in November 2025 found.

The idea that cells carry memory of an obese state as “status quo” could explain these weight regain and altering the chemical make-up of the cell to turn certain functions on and off could lead researchers to better understand treatment of obesity in the future, the study found.

“If we understand where that memory is coming from, maybe eventually we’ll have some way to stop that,” Seth Field, a professor of medicine in endocrinology at Case Western Reserve University and an author of study, told the Washington Post.

A recent study from Mayo found that about 1 in 4 participants produced lower levels of GLP-1 and other hormones that help people feel full after eating.

“Obesity is a complex disease driven by different biological mechanisms,” said the study’s senior author Andres Acosta, M.D., Ph.D., a gastroenterologist and Director of an Obesity Research program at Mayo Clinic in Minnesota. “Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease.”

The Trump administration’s pharmaceutical program, TrumpRx.gov also provided “massive discounts on popular medications used to treat obesity and infertility” such as GLP-1s, a White House official told the Daily Caller News Foundation.

“In July of 2026, senior citizens without access to GLP-1 coverage to treat obesity gained access for just $50 per month,” the official added. “In the two months since the launch of this program, 600,000 seniors have saved a total of $216 million dollars on these life-changing medicines.”

Despite the popularity of the quick-fix solution GLP-1 drugs seem to provide, they have also contributed to climbing healthcare costs, previous reporting from the DCNF found. Several U.S. small business insurance companies have stopped their coverage of the drugs, due to its continued adoption and hight costs.

“The main reason for rising health insurance costs is simply that ‘healthcare’ includes more and more things every year,” Chris Pope from the Manhattan Institute told the DCNF in August.

“This is most obvious in the case of drugs, such as Ozempic, which didn’t even exist a few years ago,” Pope said at the time. “They cost thousands of dollars per course of treatment, and millions of patients are now using them. Insurers often pick up most of this cost. A similar dynamic exists with new hospital services: whenever a hospital upgrades its equipment, opens a new building, or deploys a new surgical procedure which previously didn’t exist, spending on hospital care increases enormously.”